The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

BACKGROUND: HER2-positive breast cancers exhibit high rates of innate and acquired resistance to trastuzumab (TZ), a HER2-directed antibody used as a first line treatment for this disease. TZ resistance may in part be mediated by frequent co-expression of EGFR and by sustained activation of the mamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Dragowska, Wieslawa H, Weppler, Sherry A, Qadir, Mohammed A, Wong, Ling Yan, Franssen, Yannick, Baker, Jennifer HE, Kapanen, Anita I, Kierkels, Guido JJ, Masin, Dana, Minchinton, Andrew I, Gelmon, Karen A, Bally, Marcel B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207940/
https://www.ncbi.nlm.nih.gov/pubmed/21961653
http://dx.doi.org/10.1186/1471-2407-11-420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207940/
https://www.ncbi.nlm.nih.gov/pubmed/21961653
http://dx.doi.org/10.1186/1471-2407-11-420

Ejemplares similares